E
Ironwood Pharmaceuticals, Inc.
IRWD
$1.45
-$0.09-5.84%
E
Sell
11/8/2024Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to E+ from D on 11/8/2024 due to a significant decline in the efficiency index, valuation index and total return index. Total capital declined 4.71% from $318.53M to $303.54M.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to E+ from D on 11/8/2024 due to a significant decline in the efficiency index, valuation index and total return index. Total capital declined 4.71% from $318.53M to $303.54M.
D
Sell
8/15/2024Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D from D- on 8/15/2024 due to a significant increase in the efficiency index, growth index and valuation index. EBIT increased 139.54% from $11.46M to $27.44M, earnings per share increased from -$0.03 to -$0.0054, and net income increased 79.34% from -$4.16M to -$860.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D from D- on 8/15/2024 due to a significant increase in the efficiency index, growth index and valuation index. EBIT increased 139.54% from $11.46M to $27.44M, earnings per share increased from -$0.03 to -$0.0054, and net income increased 79.34% from -$4.16M to -$860.
D
Sell
2/16/2024Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D- from D on 2/16/2024 due to a decline in the efficiency index and valuation index. Net income declined 107.09% from $15.32M to -$1.09M, and total capital declined 11.02% from $414.97M to $369.24M.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D- from D on 2/16/2024 due to a decline in the efficiency index and valuation index. Net income declined 107.09% from $15.32M to -$1.09M, and total capital declined 11.02% from $414.97M to $369.24M.
D
Sell
1/8/2024Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D from D- on 1/8/2024 due to an increase in the volatility index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D from D- on 1/8/2024 due to an increase in the volatility index.
D
Sell
8/22/2023Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D- from D on 8/22/2023 due to a decline in the volatility index and total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D- from D on 8/22/2023 due to a decline in the volatility index and total return index.
D
Sell
8/10/2023Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D from C on 8/10/2023 due to a significant decline in the efficiency index, valuation index and growth index. Earnings per share declined from $0.2509 to -$6.84, net income declined 2,423.55% from $45.71M to -$1.06B, and total capital declined 58.23% from $1.12B to $468.97M.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D from C on 8/10/2023 due to a significant decline in the efficiency index, valuation index and growth index. Earnings per share declined from $0.2509 to -$6.84, net income declined 2,423.55% from $45.71M to -$1.06B, and total capital declined 58.23% from $1.12B to $468.97M.
C
Hold
2/22/2023Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 2/22/2023 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.2788 to $0.2699, total revenue declined 1.32% from $108.64M to $107.2M, and EBIT declined 0.16% from $68.47M to $68.36M.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 2/22/2023 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from $0.2788 to $0.2699, total revenue declined 1.32% from $108.64M to $107.2M, and EBIT declined 0.16% from $68.47M to $68.36M.
C
Hold
1/11/2023Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C+ from B- on 1/11/2023 due to a decline in the total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C+ from B- on 1/11/2023 due to a decline in the total return index.
B
Buy
12/27/2022Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to B- from C+ on 12/27/2022 due to an increase in the volatility index and total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to B- from C+ on 12/27/2022 due to an increase in the volatility index and total return index.
C
Hold
12/7/2022Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 12/7/2022 due to an increase in the volatility index and total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 12/7/2022 due to an increase in the volatility index and total return index.
C
Hold
11/22/2022Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 11/22/2022 due to a decline in the volatility index and valuation index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 11/22/2022 due to a decline in the volatility index and valuation index.
C
Hold
11/7/2022Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 11/7/2022 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from $0.2066 to $0.2788, EBIT increased 23.03% from $55.66M to $68.47M, and operating cash flow increased 12.59% from $61.37M to $69.09M.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 11/7/2022 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from $0.2066 to $0.2788, EBIT increased 23.03% from $55.66M to $68.47M, and operating cash flow increased 12.59% from $61.37M to $69.09M.
C
Hold
9/16/2022Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 9/16/2022 due to a large decline in the valuation index, growth index and volatility index. Operating cash flow declined 4.3% from $64.12M to $61.37M, EBIT declined 3.79% from $57.85M to $55.66M, and earnings per share declined from $0.2106 to $0.2066.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 9/16/2022 due to a large decline in the valuation index, growth index and volatility index. Operating cash flow declined 4.3% from $64.12M to $61.37M, EBIT declined 3.79% from $57.85M to $55.66M, and earnings per share declined from $0.2106 to $0.2066.
C
Hold
7/20/2022Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C+ from B- on 7/20/2022 due to a decline in the total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C+ from B- on 7/20/2022 due to a decline in the total return index.
B
Buy
6/15/2022Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to B- from C+ on 6/15/2022 due to an increase in the total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to B- from C+ on 6/15/2022 due to an increase in the total return index.
C
Hold
5/31/2022Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C+ from B- on 5/31/2022 due to a decline in the total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C+ from B- on 5/31/2022 due to a decline in the total return index.
B
Buy
5/13/2022Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to B- from C+ on 5/13/2022 due to an increase in the total return index, efficiency index and volatility index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to B- from C+ on 5/13/2022 due to an increase in the total return index, efficiency index and volatility index.
C
Hold
4/18/2022Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 4/18/2022 due to an increase in the growth index, efficiency index and total return index. Total revenue increased 12.9% from $103.75M to $117.13M, and total capital increased 3.01% from $1.05B to $1.08B.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 4/18/2022 due to an increase in the growth index, efficiency index and total return index. Total revenue increased 12.9% from $103.75M to $117.13M, and total capital increased 3.01% from $1.05B to $1.08B.
C
Hold
1/26/2022Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 1/26/2022 due to a noticeable decline in the total return index and growth index. Earnings per share declined from $2.39 to $0.34, and total revenue declined 0.27% from $104.03M to $103.75M.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 1/26/2022 due to a noticeable decline in the total return index and growth index. Earnings per share declined from $2.39 to $0.34, and total revenue declined 0.27% from $104.03M to $103.75M.
C
Hold
10/7/2021Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 10/7/2021 due to an increase in the total return index and volatility index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 10/7/2021 due to an increase in the total return index and volatility index.
C
Hold
9/22/2021Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 9/22/2021 due to a decline in the solvency index and volatility index. The quick ratio declined from 22.27 to 4.43.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C from C+ on 9/22/2021 due to a decline in the solvency index and volatility index. The quick ratio declined from 22.27 to 4.43.
C
Hold
8/2/2021Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 8/2/2021 due to a large increase in the total return index and volatility index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C+ from C on 8/2/2021 due to a large increase in the total return index and volatility index.
C
Hold
5/17/2021Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C from C- on 5/17/2021 due to an increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 15.07 to 22.27, debt to equity declined from 6.92 to 3.99, and total capital increased 10.25% from $516.34M to $569.28M.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C from C- on 5/17/2021 due to an increase in the valuation index, solvency index and efficiency index. The quick ratio increased from 15.07 to 22.27, debt to equity declined from 6.92 to 3.99, and total capital increased 10.25% from $516.34M to $569.28M.
C
Hold
4/20/2021Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C- from C on 4/20/2021 due to a decline in the volatility index and total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C- from C on 4/20/2021 due to a decline in the volatility index and total return index.
C
Hold
4/5/2021Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C from C- on 4/5/2021 due to an increase in the volatility index and valuation index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C from C- on 4/5/2021 due to an increase in the volatility index and valuation index.
C
Hold
3/18/2021Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C- from C on 3/18/2021 due to a decline in the valuation index, volatility index and total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to C- from C on 3/18/2021 due to a decline in the valuation index, volatility index and total return index.
C
Hold
2/19/2021Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C from C- on 2/19/2021 due to a significant increase in the solvency index, growth index and valuation index. Debt to equity declined from 72.43 to 6.92, EBIT increased 41.17% from $46.85M to $66.13M, and earnings per share increased from $0.21 to $0.2696.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C from C- on 2/19/2021 due to a significant increase in the solvency index, growth index and valuation index. Debt to equity declined from 72.43 to 6.92, EBIT increased 41.17% from $46.85M to $66.13M, and earnings per share increased from $0.21 to $0.2696.
C
Hold
5/20/2020Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C- from D+ on 5/20/2020 due to a significant increase in the valuation index, growth index and efficiency index. Operating cash flow increased 58.1% from $27.58M to $43.6M, and total capital increased 8.11% from $337.97M to $365.37M.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C- from D+ on 5/20/2020 due to a significant increase in the valuation index, growth index and efficiency index. Operating cash flow increased 58.1% from $27.58M to $43.6M, and total capital increased 8.11% from $337.97M to $365.37M.
D
Sell
5/1/2020Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D+ from D on 5/1/2020 due to a significant increase in the efficiency index, valuation index and growth index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D+ from D on 5/1/2020 due to a significant increase in the efficiency index, valuation index and growth index.
D
Sell
3/4/2020Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D from D+ on 3/4/2020 due to a decline in the total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D from D+ on 3/4/2020 due to a decline in the total return index.
D
Sell
2/18/2020Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D+ from D on 2/18/2020 due to a large increase in the efficiency index, total return index and volatility index. Net income increased 131.78% from $20.65M to $47.86M, and total capital increased 19.75% from $282.22M to $337.97M.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D+ from D on 2/18/2020 due to a large increase in the efficiency index, total return index and volatility index. Net income increased 131.78% from $20.65M to $47.86M, and total capital increased 19.75% from $282.22M to $337.97M.
D
Sell
11/5/2019Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D from D- on 11/5/2019 due to a substantial increase in the growth index and efficiency index. EBIT increased 247.77% from $18.9M to $65.72M, net income increased 68.1% from $12.28M to $20.65M, and earnings per share increased from $0.0788 to $0.132.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D from D- on 11/5/2019 due to a substantial increase in the growth index and efficiency index. EBIT increased 247.77% from $18.9M to $65.72M, net income increased 68.1% from $12.28M to $20.65M, and earnings per share increased from $0.0788 to $0.132.
D
Sell
12/12/2018Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D- from D on 12/12/2018 due to a decline in the volatility index and total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D- from D on 12/12/2018 due to a decline in the volatility index and total return index.
D
Sell
11/8/2018Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D from D+ on 11/8/2018 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 253.08% from -$49.38M to -$174.35M, earnings per share declined from -$0.3245 to -$1.1379, and total capital declined 41.63% from $363.2M to $212.01M.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D from D+ on 11/8/2018 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 253.08% from -$49.38M to -$174.35M, earnings per share declined from -$0.3245 to -$1.1379, and total capital declined 41.63% from $363.2M to $212.01M.
D
Sell
8/8/2018Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D+ from C- on 8/8/2018 due to a decline in the growth index, total return index and efficiency index. Net income declined 14.45% from -$43.14M to -$49.38M, earnings per share declined from -$0.2857 to -$0.3245, and EBIT declined 7.99% from -$32.93M to -$35.57M.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D+ from C- on 8/8/2018 due to a decline in the growth index, total return index and efficiency index. Net income declined 14.45% from -$43.14M to -$49.38M, earnings per share declined from -$0.2857 to -$0.3245, and EBIT declined 7.99% from -$32.93M to -$35.57M.
C
Hold
7/23/2018Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C- from D+ on 7/23/2018 due to a noticeable increase in the total return index and volatility index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to C- from D+ on 7/23/2018 due to a noticeable increase in the total return index and volatility index.
D
Sell
5/7/2018Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D+ from D on 5/7/2018 due to an increase in the efficiency index, volatility index and growth index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D+ from D on 5/7/2018 due to an increase in the efficiency index, volatility index and growth index.
D
Sell
1/17/2018Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D from D+ on 1/17/2018 due to a decline in the volatility index and total return index.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D from D+ on 1/17/2018 due to a decline in the volatility index and total return index.
D
Sell
11/3/2017Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D+ from D on 11/3/2017 due to a major increase in the total return index, volatility index and valuation index.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D+ from D on 11/3/2017 due to a major increase in the total return index, volatility index and valuation index.
D
Sell
5/13/2016Upgraded
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D from D- on 5/13/2016 due to an increase in the growth index, efficiency index and volatility index. Operating cash flow increased 100.83% from -$19.36M to $161, EBIT increased 66.23% from -$5.83M to -$1.97M, and total revenue increased 23.89% from $53.31M to $66.04M.
Ironwood Pharmaceuticals, Inc. (IRWD) was upgraded to D from D- on 5/13/2016 due to an increase in the growth index, efficiency index and volatility index. Operating cash flow increased 100.83% from -$19.36M to $161, EBIT increased 66.23% from -$5.83M to -$1.97M, and total revenue increased 23.89% from $53.31M to $66.04M.
D
Sell
3/11/2016Downgrade
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and solvency index. The quick ratio declined from 7.37 to 6.46, and debt to equity increased from 3.8 to 4.01.
Ironwood Pharmaceuticals, Inc. (IRWD) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and solvency index. The quick ratio declined from 7.37 to 6.46, and debt to equity increased from 3.8 to 4.01.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
